{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T10:56:16Z","timestamp":1761216976423},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CDT"],"published-print":{"date-parts":[[2006,5,1]]},"DOI":"10.2174\/138945006776818656","type":"journal-article","created":{"date-parts":[[2006,4,25]],"date-time":"2006-04-25T23:12:21Z","timestamp":1146006741000},"page":"629-637","source":"Crossref","is-referenced-by-count":5,"title":["Protease-Activated Receptors (PARs) are Partly Pro-Inflammatory and Partly Anti-Inflammatory: Will PAR Agonists or Antagonists Participate in Future Drug Therapies?"],"prefix":"10.2174","volume":"7","author":[{"given":"B.","family":"De Campo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/55936","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T08:55:07Z","timestamp":1448268907000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/openurl\/content.php?genre=article&issn=1389-4501&volume=7&issue=5&spage=629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,1]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/138945006776818656","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5,1]]}}}